Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Similar documents
Diabetes Medications: Oral Anti-Hyperglycemic Medications

Non-Insulin Diabetes Medications Summary

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

DM Fundamentals Class 4 Meds for Type 2

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

Pharmacologic Agents for Treatment of Type 2 Diabetes

Oral and Injectable Non-insulin Antihyperglycemic Agents

What s New in Diabetes Treatment. Disclosures

Diabetes Treatment Guidelines

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

DM Fundamentals Class 4 Meds for Type 2

I. General Considerations

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

ORAL AGENTS OLD & NEW FOR THE MANAGEMENT OF T2DM

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes Mellitus hypoglycaemic agents

What s New in Diabetes Medications. Jena Torpin, PharmD

Oral and Injectable Medication Options for Diabetes Treatment

The information in this guide comes from a government-funded review of research about pills for type 2 diabetes.

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Table 1. Antihyperglycemic agents for use in type 2 diabetes

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Drug Class Review Newer Diabetes Medications and Combinations

How to Fight Diabetes and Win. Diabetes. Medications

Drug Class Monograph

Diabetes Management: A diagnostic perspective

Newer Drugs in the Management of Type 2 Diabetes Mellitus

Date of Review: September 2016 Date of Last Review: September 2015

Victoza (Liraglutide) Solution for Injection

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Glycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University

Understanding Your Diabetes: A Basic Guide

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

Very Practical Tips for Managing Type 2 Diabetes

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Drug Class Monograph

SGLT2 Inhibitors

Treatment Options for Diabetes: An Update

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Glucose Control drug treatments

SGLT2 Inhibitors

New Therapies for Diabetes

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES

The Death of Sulfonylureas? A Review of New Diabetes Medications

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

Diabetes 2016: Strategies for achieving optimal diabetes control

Update on Diabetes Mellitus

Dept of Diabetes Main Desk

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

Diabetes Mellitus II CPG

Copyright 2003 How long does it take metformin to lower blood sugar. All rights reserved.

How can we improve outcomes in Type 2 diabetes?

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

Quick Guide MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria

Welcome to the PHASE Learning Community! October 31, 2018

A New Therapeutic Strategey for Type II Diabetes: Update 2008

Antidiabetic Agents CHAPTER BIGUANIDES

Diabetes: Just the Basics

The Community Pharmacist s Role in Diabetes Treatment

SGLT2 Inhibitors

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Diabetes, Drugs and Dangerous Discrepancies. Sally Bodenhamer, OD, OT/L, CDE

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.

Diabetes management in liver and kidney disease

Managing Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM

Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** Existing Drug Classes

Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes

Advanced Practice Education Associates. Endocrine

Wayne Gravois, MD August 6, 2017

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

PRINCIPLES OF ORAL ANTIDIABETIC AND

2018 Diabetes Summit Managing Diabetes: An Art and a Science

SGLT2 Inhibitors

What s New on the Horizon: Diabetes Medication Update

Nurse practitioners on the front lines of diabetes diagnosis and management

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Transcription:

Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase: 3-12mg) with meal Sulfonylurea Meglitinides D-Phenylalanine Stimulating insulin secretion from the pancreas Stimulates insulin secretion to reduce peaks in glucose after meal Stimulates rapid insulin secretion to reduce peaks in glucose after meal 5, 10 mg tabs, Dosing: 2.5-40 mg 1/2 hour before meals 2.5, 5, 10 mg tabs, Dosing: 2.5-20 mg with or without meal 1, 2, 4 mg tabs, Dosing: 1-8 mg with meal 0.5, 1, 2 mg tabs Dosing: Daily max 16 mg, Take before each meal 60, 120 mg tabs, Dosing: 60-180 mg with meal, Daily max 540 mg 10-18 Hours 16-2-6 Hours About 1.5 Hours nausea, heartburn, weight gain, diarrhea nausea, weight gain, diarrhea dizziness, headache, weight gain, diarrhea, flatulence dizziness, nausea headache, weight gain diarrhea, dizziness (Glucophage) (Glucophate XR) Decreases liver 500, 850, 1000 mg tabs, Dosing 500-2250 mg with meals 500-2000 mg, Dosing: Once daily with evening meal 6-12 Hours, Effective within a day or two, with maximum effect within 2 weeks Diarrhea, nausea, vomiting, abdominal bloating, flatulence, anorexia, lactic acidosis (rare). Kidney test initially and at least Acarbose (Precose), Miglitol (Glyset) Alpha-Glucosidase Inhibitor Delays the digestion of carbohydrates 50, 100 mg tabs, Dosing: 25-300 mg with first bite of food Less than 4 Hours GI sx (may decrease with time): diarrhea, abdominal pain, flatulence Actos (Pioglitazone HCL) 0.5-1.0%) sensitivity in muscle and fat 15, 30 mg tabs, Dosing: 15-45mg Works gradually when initiated, minimal effect first week with increasing effect up to 12-16 weeks; >3-4 weeks duration Edema, weight gain, dilutional anemia. Liver function tests initially and periodically 3/5/2018 Diabetes Oral Drug List 1 of 5

**Avandia (Rosiglitazone Maleate) sensitivity in muscle and fat 2, 4, 8 mg tabs, Dosing: 4-8 mg with or without food Januvia 100 mg once daily as monotherapy or as combination with other oral agents;, Eliminated via kidney URI, stuffy nose or sore throat, headache. Not with type 1 or pregnant women. A dosage reduction is recommended for renal insufficiency (see PI for recommendation) Tradjenta (Linagliptin) Onglyza (Saxagliptin) DPP-4 Inhibitor 0.6-0.8%) Slows the inactivation of incretin hormones in the intestines. release and decreases glucagon levels in the circulation, glucose dependent, slows gastric emptying 5 mg once daily. With or without food as monotherapy or with, Amaryl or Actos. Eliminated via feces 2.5 or 5 mg once daily, with or without food; can be used alone or with other oral agents. Eliminated via feces, kidneys URI, stuffy nose or sore throat, muscle pain and headache URI, UTI, headache, fluid retention (if with TZD's), hypoglycemia (if with SU), hypersensitivity events; decreased dose with renal impariment. Decrease dose for pt using CYP3 A4/5 (ketoconazole) Nesina (Alogliptin) 25 mg once daily ; can be used alone or with other oral agents. Eliminated via kidney 24+ Hours URI, UTI, headache, fluid retention (if with TZD's), hypoglycemia (if with SU), hypersensitivity events; decreased dose with renal impariment; Heptatic effects possible so check LFT's before intiating 3/5/2018 Diabetes Oral Drug List 2 of 5

Invokana (Canagliflozin) Farxiga (Dapagliflozin) Jardiance (Empagliflozin) SGLT2 (Sodium glucose cotransporter inhibitor) 0.7-1.5% SGLT2 can be used w/, insulin, DPP-4, GLP1, SU, glinides, TZD, α-glucosides All SGLT2 decrease renal glucose reabsorption and increases urine glocose excretion and lower weight 1-3 lbs 100 mg daily before the first meal of the day (dose reduction recommended if GFR increases to 300 mg if needed for improved BG control. If GFR <45, stop Invokana 5, 10 mg once daily If GFR <60, stop Farxiga Avocid if bladder cancer 10, 25 mg once daily Do not start Jardiance if GFR <45 Peak 1-2 hours after given, half-life 10.6-13.1 hours with 300 mg dose respectively, reaches steady state in body after 4-5 days of taking drug Vaginal yeast infections, UTI's, increased urination. Less common is thirst, nausea and constipation. Warnings: hypotension impariment of renal function,elevated potassium, hypoglycemia if with insulin or SU's. hypersensitivity, increased LDL, genital mycotic infections. Drug interactions: Rifampin Digoxin Glucovance (Glyburide and ) Sulfonylurea and Stimulates insulin release and decreases liver 1.25/250 mg, 2.5/500 mg, 5.0/500 mg Dosing: max 20/2000 mg. Take with meals 12 Hours dizziness, lactic acidosis (rare). Kidney test initially and at least annaully **Avandamet and decreases liver 1/500 mg, 2/500 mg, 4/500 mg, 2/1000 mg, 4/1000 mg Dosing: max 8/2000 mg daily. Take with meals. >3-4 Weeks Edema, weight gain, dilutional anemia, vomiting, abdominal, bloating, anorexia, lactic acidosis. Kidney and liver function tests initially and periodically Metaglip and Sulfonylurea Decreases liver and stimulates insuline production 2.5/250 mg, 2.5/500 mg, 5/5200 mg, Dosing: Max per day: 20/2000 mg. Take with meals 6-18 Hours Diarrhea, abdominal pain, dizziness, hypoglycemia, lactic acidosis (rare). Kidney test intially and at least 3/5/2018 Diabetes Oral Drug List 3 of 5

**Avandaryl (Avandia and Amaryl) and Sulfonylurea stimulates insulin secretion 50/1000 mg; mg. Twice daily with food >3-4 Weeks Edema, anemia, weight gain, hypoglycemiak dizziness, nausea. Liver function test initially and periodically Janumet Januvia actions plus decreasing liver 50/1000 mg; mg daily, Twice daily with food Januvia side effects plus vomiting, abdominal discomfort, indigestion, flatulence, lactic acidosis (rare). Kidney test intially and at least Janumet XR (Sitagliptin and ER) 100/1000 mg, 50/1000 mg, mg daily Januvia and ER side effects Kombiglyze (Saxagliptin and ER) Onglyza actions pluse decreasing liver 5/500 mg, 5/1000 mg, Max dose: 5/2000 mg daily, with evening meal Onglyza side effects plus side effects Glyxambi (Jardiance and Tradjenta) SGLT2 and DPP-4 Inhibitor see SGLT2 and DPP-4 10/25 mg, 25/5 mg, once daily in the morning with or without food Renal impariment. Do not initiate if egfr <45 ml/min/1.73m 2 d/c if egfr drops to <45mL/min/1.73m 2 XigduOXR (Farxiga and ) SGLT2 and see SGLT2 and 5/1000 mg not to exceed 2:10/2000 mg, once daily in the morning with food Contraindicated CrCl <60 ml or ESRD 3/5/2018 Diabetes Oral Drug List 4 of 5

Synjardy (Jardiance and ) SGLT2 and see SGLT2 and 5/5020 mg, 5/1000 mg, 12.5/500 mg, 12.5/1000 mg (max dose), twice daily with food. Increase dose gradually Do not initiate if egfr <45 ml/min/1.73m 2 d/c if egfr drops to <45mL/min/1.73m 2 Do not initiate or continue if Cr > 1.5 mg/dl M) or 1.4 mg/dl (F) Jentadueto (Tradjenta and ) DDP-4 Inhibitor and Biduanide Tradjenta actions plus decreasing liver 2.5/500 mg, 2.5/850 mg, Max dose: 2.5/1000 mg twice daily. Should be given twice daily with meals, with gradual dose escalation to reduce gastrointestinal side effects of. Tradjenta and side effects Duetact (Actos and Amaryl) Kazano (Alogliptin and ) Oseni (Alogliptin and Actos) and Sulfonylurea stimulates insulin secretion Algoliptin and actions Alogliptin and Actos actions 30/2 mg, 30/4 mg, Once daily 12.5/500 mg, 1 twice daily, not to exceed 25/2000 mg. Titrate gradually to prevent GI side effects possible with 12.5/15 mg 12.5/30 mg 12.5/45 mg 25/15 mn 25/30 mg 24/45 mg once daily with or without food > 3-4 Weeks > 3-4 Weeks Actos and Amaryl side effects Algoliptin and side effects Aloglitpin and Actos side effects 3/5/2018 Diabetes Oral Drug List 5 of 5